Is shared care with annual hospital review better value for money than predominantly hospital-based care in patients with established stable rheumatoid arthritis?

Annals of the Rheumatic Diseases

Volumn 66, Issue 5, 2007, Pages 658-663

  Davies, Linda Mary ^a,b   Fargher, Emily Anne ^b   Tricker, Karen ^b   Dawes, Peter ^c   Scott, David L ^d   Symmons, Deborah ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY HOSPITALS OF NORTH MIDLANDS NHS TRUST   (United Kingdom)

^d KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; ECONOMIC ASPECT; HEALTH CARE; HEALTH CARE COST; HOSPITAL CARE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; SYMPTOM;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; DELIVERY OF HEALTH CARE; FAMILY PRACTICE; GREAT BRITAIN; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME;

EID: 34248154809     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.061234     Document Type: Article

References (41)

1. van Gestel AM, Stucki G. Evaluation of established rheumatoid arthritis. Baillieres Best Pract Res Clin Rheumatol 1999;13:629- 44.
2. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000;43:22-9.
3. Fries JF, Williams CA, Morfeld D, Singh G, Sibley J. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis Rheum 1996;39:616-22.
4. Wolfe F, Hawley DJ, Cathey AM. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990;17:994-1002.
5. Morand EF, McCloud PI, Littlejohn GO. Life table analysis of 879 treatment episodes with slow acting antirheumatic drugs in community rheumatology practice. J Rheumatol 1992;19:704-8.
6. Munro R, Hampson R, McEntegart A, Thomson EA, Madhok R, Capell H. Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective study. Ann Rheum Dis 1998;57:88-93.
7. O'Dell JR. Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 2002;46:283-5.
8. Egsmose C, Lund B, Borg G, Pettersson H, Berg E, Brodin U, et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J Rheumatol 1995;22:2208-13.
9. Tsakonas E, Fitzgerald AA, Fitzcharles MA, Cividino A, Thorne JC, M'Seffar A, et al. Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. J Rheumatol 2000;27:623- 9.
10. van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, Booma-Frankfort C, van der Veen MJ, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996;124:699-707.
11. Stenger AA, van Leeuwen MA, Houtman PM, Bruyn GA, Speerstra F, Barendsen BC, et al. Early effective suppression of inflammation in rheumatoid arthritis reduces radiographic progression. Br J Rheumatol 1998;37:1157-63.
12. Albers JM, Paimela L, Kurki P, Eberhardt KB, Emery P, 't Hof MA, et al. Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis. Ann Rheum Dis 2001;60:453-8.
13. Symmons DP, Jones AM, Scott DL, Prior P. Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well J Rheumatol 1998;25:1072-7.
14. Landewe RB, Boers M, Verhoeven AC, Westhovens R, van de Laar AM, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum 2002;46:347-56.
15. Symmons D, Tricker K, Harrison M, Roberts C, Davis M, Dawes P, et al. Patients with stable long-standing rheumatoid arthritis continue to deteriorate despite intensified treatment with traditional disease modifying anti-rheumatic drugs - results of the British Rheumatoid Outcome Study Group randomized controlled clinical trial. Rheumatology (Oxford) 2006;45:558-65.
16. Symmons D, Tricker K, Roberts C, Davies L, Dawes P, Scott DL. The British Rheumatoid Outcome Study Group (BROSG) randomised controlled trial to compare the effectiveness and cost-effectiveness of aggressive versus symptomatic therapy in established rheumatoid arthritis. Health Technol Assess 2005;9:iii-iv, ix-x, 1-78.
17. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
18. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137-45.
19. Kirwan JR, Reeback JS. Stanford Health Assessment questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986;25:206-9.
20. Briggs AH. A Bayesian approach to stochastic cost-effectiveness analysis. Health Econ 1999;8:257-61.
21. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10:779-87.
22. Pedram-Sendi P, Briggs AH. Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane. Health Econ 2001;10:675-80.
23. Briggs AH, O'Brien BJ. The death of cost minimisation analysis? Health Econ 2003;10:179-84.
24. EuroQol Group. EuroQol - new facility for the measurement of health related quality of life. Health Policy 2003;16:199-208.
25. Dolan P, Gudex C, Kind P, William A. A social tariff for EuroQuol: results from a UK general population survey. University of York, York: Centre for Health Economics Discussion Paper 138, 1995.
26. Netten A, Curtis L. Unit costs of health and social care. Personal Social Services Research Unit, University of Kent at Canterbury, 2002.
27. Statistical Solutions. SOLAS for missing data analysis Version 3.2. Cork, Ireland: Statistical Solutions Ltd, 2001.
28. Rubin DB, Schenker N. Multiple imputation in health-care data bases: an overview and some applications. Stat Med 1991;10:585-98.
29. Lavori PW, Dawson R, Shera D. A multiple imputation strategy for clinical trials with truncation of patient data. Stat Med 1995;14:1913-25.
30. Kobelt G, Jonsson L, Lindgren P, Young A, Eberhardt K. Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheumatism 2002;46:2310-9.
31. Van Den Hout WB, Tijhuis GJ, Hazes JMW, Breedveld FC, Vliet Vlieland TPM. Cost effectiveness and cost utility analysis of mulfidisciplinary care in patients with rheumatoid arthritis: A randomised comparison of clinical nurse specialist care, inpatient team care, and day patient team care. Ann Rheum Dis 2003;62:308-15.
32. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 2000;39:28-33.
33. Gabriel SE, Wagner JL, Zinsmeister AR, Scott CG, Luthra HS. Is rheumatoid arthritis care more costly when provided by rheumatologists compared with generalists? Arthritis Rheum 2001;44:1504-14.
34. Ruof J, Hulsemann JL, Mittendorf T, Handelmann S, Von Der Schulenburg JM, Zeidler H, et al. Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources. Ann Rheum Dis 2003;62:544-50.
35. Ward MM, Javitz HS, Yelin EH. The direct cost of rheumatoid arthritis. Value in Health 2000;3:243-52.
36. Lajas C, Abasolo L, Bellajdel B, Hernandez-Garcia C, Carmona L, Vargas E, et al. Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum 2003;49:64-70.
37. National Institute for Clinical Excellence. Guide to the methods of technology appraisal NO515. London: National Institute for Clinical Excellence, 2004.
38. Netten A, Curtis L. Unit costs of health and social care. Canterbury: Personal Social Services Research Unit, University of Kent at Canterbury, 2002.
39. Department of Health. Reference costs, 2001. http://www.doh.gov.uk/nhsexec (acessed 5 Febraury 2007).
40. The Chartered Institute of Public Finance, Accountancy (CIPFA). The Health Service Financial Database and Comparative Tool 2001. Croydon: Institute of Public Finance Limited, 2002.
41. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ 2004;329:224-7.